.png)
The Pharma Letter Podcast
The Pharma Letter Podcast provides in-depth discussion and analysis focused on key trends, companies and events in the pharmaceutical and biotech industries. Our guests come from a broad array of sectors and business functions, from early stage research in biopharmaceuticals, to patient engagement and marketing, supply chain management and life sciences investing. Podcasts are typically 20-30 minutes in length and are released approximately once every two weeks.
The Pharma Letter Podcast
How can we use AI to program antibodies?
•
Simon Wentworth
•
Season 1
•
Episode 29
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases.
We are joined by Yanay Ofran, chief executive and founder of Israel-based Biolojic Design, a company that is working on programmable antibodies.
Biolojic's platform has already yielded a first-of-its-kind computationally designed antibody, now in Phase II trials, as well as a pipeline aimed at autoimmune and inflammatory conditions.
The firm has also forged collaborations with major players in the industry, including fellow Israeli firm Teva (NYSE: TEVA), as well as Eli Lilly (NYSE: LLY) and Germany’s Merck KGaA (MRK: DE).
.png)